Focus: Corcept Therapeutics is a small-molecule biotech focused on endocrine and oncology disorders, with a market presence centered on its flagship Cushing's syndrome therapy. The company operates at mid-cap scale (201-500 employees) from Redwood City, California.
Profile data last refreshed 58m ago · AI intelligence enriched 2mo ago
Hot — 80 jobs added in 30d
Net +75 (80 new, 5 removed). Aggressive expansion phase.
Corcept offers stability and scientific depth for endocrinology specialists, but single-product dependency and minimal hiring limit career mobility and growth opportunities.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole revenue engine with 14-year exclusivity runway; accounts for 100% of company revenue.
Help build intelligence for Corcept Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Corcept Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Late-stage development for psychiatric indication but faces uncertain LOE timeline and competitive pressure.
Corcept (CORT) chief business officer reports 7,300-share gift of common stock - Stock Titan
Corcept (CORT) chief business officer reports 7,300-share gift of common stock Stock Titan
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) ChartMill
Corcept Therapeutics (CORT) Receives Upgrade, Stock Surges Over 7% - GuruFocus
Corcept Therapeutics (CORT) Receives Upgrade, Stock Surges Over 7% GuruFocus
Corcept (CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
Corcept (CORT) CDO sells 20K shares under 10b5-1 plan Stock Titan
Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel - Stock Titan
Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel Stock Titan
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan - Stock Titan
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo